Argos Therapeutics, Inc. (Argos) is a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s advanced product candidate is AGS-003, which the Company is developing for the treatment of metastatic renal cell carcinoma (mRCC) and other cancers. The Company is also developing AGS-004, its second Arcelis-based product candidate, for the treatment of Human Immunodeficiency Virus (HIV). The Company is conducting a Phase III clinical trial of AGS-003 plus sunitinib/targeted therapy for the treatment of newly diagnosed mRCC under a special protocol assessment (SPA) with the Food and Drug Administration (FDA). The Company has completed three clinical trials of AGS-004. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate personalized immunotherapies.
